Perampanel (Epilepsy) - Medication and Pregnancy KB

Perampanel (Epilepsy)

Exposed non-exposed, cohort studies

Study	Country Study period Study design	Data source	Exposure definition	Non-exposure definition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias
The Kerala Registry for Epilepsy and Pregnancy (Epilepsy) (Controls exposed to Lamotrigine) 2024	India 1998 - 2023 prospective cohort	The Kerala Registry of Epilepsy and Pregnancy (KREP)	Children of women with epilepsy using Perampanel monotherapy any time during the first trimester of pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study).	exposed to other treatment, sick Children of women with epilepsy using lamotrigine monotherapy any time during the first trimester of pregnancy.	1st trimester	2 / 50	Data extracted from the publication Perucca 2024, an update of the Epilepsy-pregnancy registries. Study design and control data based on Thomas et al., 2017 and Thomas et al., 2021.
	India 1998 - 2023 prospective cohort	The Kerala Registry of Epilepsy and Pregnancy (KREP)	Women were instructed to record the use of the antiepileptic drugs on a daily basis in the pregnancy diary that was given to them.		1st trimester	2 / 50
The Kerala Registry for Epilepsy and Pregnancy (Epilepsy) (Controls unexposed, sick) 2024	India 1998 - 2023 prospective cohort	The Kerala Registry of Epilepsy and Pregnancy (KREP)	Children of women with epilepsy using Perampanel monotherapy any time during the first trimester of pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study).	unexposed, sick Children of women with epilepsy not using any antiepileptic drugs during the first trimester.	1st trimester	2 / 340	Data extracted from the publication Perucca 2024, an update of the Epilepsy-pregnancy registries. Study design and control data based on Thomas et al., 2017 and Thomas et al., 2021.
	India 1998 - 2023 prospective cohort	The Kerala Registry of Epilepsy and Pregnancy (KREP)	Women were instructed to record the use of the antiepileptic drugs on a daily basis in the pregnancy diary that was given to them.		1st trimester	2 / 340
The West China Registry (Epilepsy) (Controls exposed to LTG) 2024	China 2009 - 2023 prospective cohort	A prospective cohort study entitled 'Construction and Application of the Women with Epilepsy of Child-bearing Age Ontology (WWECA)', with West China Hospital of Sichuan University as the main center.	Women with epilepsy (WWE) using Perampanel monotherapy during pregnancy.	exposed to other treatment, sick Women with epilepsy (WWE) using Lamotrigine monotherapy during pregnancy.	during pregnancy (anytime or not specified)	3 / 38	Data extracted from the publication Perucca 2024, an update of the Epilepsy-pregnancy registries, and with de-depublication of pregnancies of EURAP registry. Period of exposure not specified => considered as during pregnancy.
	China 2009 - 2023 prospective cohort		The use of antiseizure medications on the included patients was registered by doctors and trained researchers.		during pregnancy (anytime or not specified)	3 / 38
The West China Registry (Epilepsy) (Controls unexposed, sick) 2024	China 2009 - 2023 prospective cohort	A prospective cohort study entitled 'Construction and Application of the Women with Epilepsy of Child-bearing Age Ontology (WWECA)', with West China Hospital of Sichuan University as the main center.	Women with epilepsy (WWE) using Perampanel monotherapy during pregnancy.	unexposed, sick Women with epilepsy (WWE) not using antiseizure medications during pregnancy.	during pregnancy (anytime or not specified)	3 / 253	Data extracted from the publication Perucca 2024, an update of the Epilepsy-pregnancy registries (and Li 2023 for control group), and with de-depublication of pregnancies of EURAP registry. Period of exposure not specified.
	China 2009 - 2023 prospective cohort		The use of antiseizure medications on the included patients was registered by doctors and trained researchers.		during pregnancy (anytime or not specified)	3 / 253

Case-control studies

Study	Country Study period Study design	Data source	Case	Control	Exposition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias

Risk of bias: : NA; : low; : moderate; : serious; : critical; : unclear;

Empty. There are no case-control studies available for this drug.

master protocol